INVO Fertility, Inc. (Nasdaq: IVF) announced their second quarter 2025 financial results, showcasing growth and advancements in their fertility services.
Revenue reached $1,863,654, setting a new quarterly record for the Company.
Clinic revenue increased to $2,188,893 with a notable 2% year-over-year growth.
Operational Achievements
INVO Fertility expanded services, launched telehealth options, and received a new patent, solidifying their position in the fertility industry.
Financial Performance
Revenue increased by 1%, reaching $1,863,654. Net loss from continuing operations was $(3.2) million.
Strategic Divestiture
The divestiture of NAYA Therapeutics, Inc. allows INVO Fertility to refocus on core fertility operations for enhanced growth.
- INVO Fertility received recognition for its Wisconsin clinic on Newsweek's List of America's Best Fertility Clinics.
- The addition of Platelet-Rich Plasma therapy and a new patent for the INVOcell device indicate a commitment to innovation and patient-centered care.
INVO Fertility's strategic decisions and operational advancements position them for continued growth and leadership in the fertility services sector.